HK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept

Tiger Newspress

26 Jun

RemeGen shares plunged 20.9% in morning trading.

RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China.

This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks.

The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1141924524"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141924524\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1141924524?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-26 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141924524","market":"hk","top_or_hot":-1,"title":"HK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept","media":"Tiger Newspress","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/09995\">RemeGen</a> shares plunged 20.9% in morning trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/65005491cf35f93b0d7eeca5d041410e\" tg-width=\"536\" tg-height=\"132\"/></p><p>RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China. </p><p>This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&amp;D risks. </p><p>The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Movers | RemeGen Shares Plunge 21% as It Partners with Vor Biopharma for Global Expansion of Telitacicept\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2025-06-26 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/09995\">RemeGen</a> shares plunged 20.9% in morning trading.</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/65005491cf35f93b0d7eeca5d041410e\" tg-width=\"536\" tg-height=\"132\"/></p><p>RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China. </p><p>This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&amp;D risks. </p><p>The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09995","symbol_name":"荣昌生物","start_time":0,"source_url":"","article_id":"1141924524","we_media_id":"1079075236","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141924524","pubTimestamp":1750902557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Tiger Newspress","introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"summary":"$RemeGen$ shares plunged 20.9% in morning trading.RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China. This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks. The agreeme","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09995":"荣昌生物"},"translate_title":"香港Movers RemeGen与Vor Biopharma合作进行Telitacicept全球扩张，股价暴跌21%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09995":1.1},"content_text":"RemeGen shares plunged 20.9% in morning trading.RemeGen Co., Ltd. has entered into a license agreement with Vor Biopharma Inc., granting Vor Bio exclusive rights to develop and commercialize Telitacicept outside Greater China. This strategic partnership, which includes a $125 million consideration and potential milestone payments up to $4,105 million, aims to accelerate the global expansion of Telitacicept, enhancing RemeGen’s brand value and cash flow while diversifying R&D risks. The agreement is expected to provide innovative treatment options worldwide and strengthen RemeGen’s position in the biotechnology industry.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}